Serious adverse events at longest · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher serious adverse events (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy showed no clear difference in adverse events (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy plus alemtuzumab showed no clear difference in serious adverse events compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).
1 finding from 1 review
All adverse events · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy may leads to higher all adverse events compared with observation (low certainty).
1 finding from 1 review
Adverse events: infections (CTCAE grade ≥ 3) (longest available · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher adverse events: infections (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
All adverse events · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy probably leads to higher all adverse events compared with placebo/observation (moderate certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy may leads to higher grade 3/4 adverse events compared with observation (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy may leads to higher grade 3/4 adverse events compared with placebo/observation (low certainty).
1 finding from 1 review
All adverse events – not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events ‐ not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events Toxic deaths · cancer patients receiving myelotoxic chemotherapy
The intervention showed no clear difference in adverse events Toxic deaths (low certainty).
1 finding from 1 review
Diarrhoea · All patients with a diagnosis of multiple myeloma
Bortezomib probably leads to higher adverse Events: Diarrhoea ‐ Bortezomib versus no bortezomib (same… compared with no bortezomib (moderate certainty).
2 findings from 1 review
Thrombocytopenia · All patients with a diagnosis of multiple myeloma
Bortezomib leads to higher adverse Events: Thrombocytopenia ‐ Bortezomib versus no bortezomib… compared with no bortezomib (high certainty).
2 findings from 1 review
Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma
Bortezomib showed no clear difference in adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib… compared with no bortezomib (high certainty).
1 finding from 1 review
Adverse effects (cardiac) · All patients with a diagnosis of multiple myeloma
Bortezomib showed no clear difference in adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib… compared with no bortezomib (moderate certainty).
1 finding from 1 review
Adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no… compared with no bortezomib (low certainty).
1 finding from 1 review
Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib… compared with no bortezomib (low certainty).
1 finding from 1 review
Adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib leads to higher adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib… compared with no bortezomib (high certainty).
1 finding from 1 review
Adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib leads to higher adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no… compared with no bortezomib (high certainty).
1 finding from 1 review